Just to go on record after my first ever rant this morning - I don't want Nadar replaced, I just want him to recognize his weaknesses and stop having unnecessary conference calls. Everything mentioned in yesterday's conference call could've been handled in few PR's. An artful Investor Relations/Public Relations pro (the lack of which is another weakness CytoDyn needs to recognize) could've even written them in a way that boosted the SP instead of tanking it. Even the EUA denial could've been dressed up a bit in a good PR. But I like Nadar's passion, he's the reason we're all here because he's the one who wouldn't give up on Pro-140/LL, and he deserves the chance to take LL across the finish line - regardless of how bad he might be on conference calls. If no S&C approval and no completed HIV BLA happen before year-end, then I reserve the right to change my opinion.
I actually abstained on the 25 million share question. Something - uplisting, completed HIV BLA/PDUFA date, S&C approval, anything substantive - needs to happen before I'd vote yes on anything like that. Time to deliver the goods. In terms of hiring talent - build it and they will come.